Investigating the synthesis of paracetamol from CST-derived β-pinene is also relevant to recent policy objectives on reshoring pharmaceutical manufacture back to local production sites, such as described in the European pharmaceutical strategy of 2020. Current paracetamol production sites are predominantly located in India and China and have a production output of 2 000 -40 000 t/y, while there is no active production of commercial paracetamol API in Europe. However, there is a growing interest to decentralise pharmaceutical production to generate shorter value chains and support regional pharmaceutical autonomy. This notion is mainly driven by social and environmental benefits that can be attained from this proposition, such as secured access to high-quality medicines and reductions in transportation related emissions. As CST is a biomass-based feedstock widely available in Europe and other regions, the synthesis of paracetamol from CST-derived β-pinene offers a potentially feasible close-to-market manufacturing option. Additionally, this case study could inspire the local manufacture of other pharmaceuticals through terpenebased methods.